The news: Anthropic made waves in pharma circles this week with two major announcements.

• At a company event, the AI startup said it plans to launch a drug discovery program while experimenting with developing medicines in-house, according to STAT.
• Separately, Anthropic unveiled Claude Science, a research platform that brings fragmented scientific tools into a single AI workbench to help scientists and pharma researchers automate their work.

Why it matters: Anthropic’s expansion into healthcare and pharma positions Claude as a platform for life sciences and healthcare workflows, helping drugmakers accelerate R&D.

• Users can assign complex research tasks to Claude, which can write code, analyze data, and synthesize findings to support work such as identifying promising drug targets or interpreting experimental results.
• Novartis CEO Vas Narasimhan told MedCity News that tools like Claude Science could help shorten the time it takes to bring a drug candidate to market from approximately 12 years to seven or eight, while improving the odds of regulatory approval.

At the same time, Anthropic may emerge as a competitive threat to drugmakers. Its entry into drug development may fuel concerns that a tech company could create and commercialize new medicines, encroaching on pharma’s traditional domain. Still, it’s far too early to draw sweeping conclusions. Anthropic executives told STAT that the company may instead focus on therapies for “neglected” diseases that aren’t a core focus for Big Pharma.

Implications for pharma companies: Other major tech players, including Google, OpenAI, and Nvidia, have introduced AI tools for pharma and life sciences companies. But Anthropic is the first AI developer to launch a dedicated platform for pharma researchers and scientists while also venturing into drug development, according to STAT. If successful, these capabilities could shorten research timelines, reduce manual scientific work, and deepen AI vendors’ role across every stage of pharma development.

Even so, large drugmakers have their own AI drug discovery tools, backed by decades of proprietary research data, giving them an advantage over tech companies that typically lack comparable in-house biomedical data sets. The more likely outcome is partnerships, with AI developers and pharma companies complementing each other’s strengths, rather than a company like Anthropic becoming a drugmaker.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.